[摘要] 目的 探讨拉帕替尼联合紫杉醇对于胃癌治疗的临床疗效及其不良反应情况。方法 方便选取2014 年 1 月—2015年1月该院收治的60例胃癌患者，随机分实验组(30例)，对照组(30例)。实验组用拉帕替尼联合紫杉醇治疗，对照组采用 5-Fu 联合紫杉醇。观察并对比疗效、临床收益率、不良反应等。 结果 实验组疗效50.0%显著高于对照组16.7%；实验组临床受益率(86.7%，76.7%，83.3%)显著优于对照组(63.3%，50.0%，60.0%)。实验组白细胞(10例)及血小板(5例)下降相比对照组(10例，6例)，差异无统计学意义，实验组血红细胞的下降(6例)相比对照组(3例)差异有统计学意义。结论 拉帕替尼联合紫杉醇治疗胃癌的疗效确切，不良反应可耐受。

 [关键词] 拉帕替尼；紫杉醇；胃癌

 [中图分类号] R735.2 [文献标识码] A [文章编号] 1674-0742(2016)09(c)-0145-03

 [Abstract] Objective Study the clinical efficacy and adverse reactions in gastric cancer treated with lapatinib combined with paclitaxel .Methods Convenient from January 2014 to January 2015 Randomly 60 cases of gastric cancer were divided into two groups. Each group had 30 cases. The experimental group treated with lapatinib combined with paclitaxel.And the control group was treated with 5-Fu combined with paclitaxel. Observe and compare the efficacy ...... 第 1 2 页 下一页
 百拇医药网 http://www.100md.com/html/paper/1674-0742/2016/27/53.htm
您现在查看是摘要页，全文长 3567 字符。